MedTrace Logo

A Clinical Trial to Evaluate the Efficacy and Safety of CKD-495

NCT04255589 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 242

Last updated 2021-07-02

No results posted yet for this study

Summary

To Evaluate the Efficacy and Safety of CKD-495

Conditions

  • Gastritis

Interventions

DRUG

CKD-495 75mg

CKD-495 75mg Tab.

DRUG

Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg

Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.

DRUG

Placebo of the CKD-495 75mg

Placebo of the CKD-495 75mg Tab.

DRUG

Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg

Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Oh Young Lee, MD, Ph.D. · Hanyang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-06
Primary Completion
2021-05-20
Completion
2021-05-20

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04255589 on ClinicalTrials.gov